share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144：擬議出售證券
美股SEC公告 ·  09/05 01:20
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 20,000 Class A shares of the company on 09/04/2024, with an aggregate market value of $120,800. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 250,000 shares were sold for gross proceeds of $1,961,500.
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 20,000 Class A shares of the company on 09/04/2024, with an aggregate market value of $120,800. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 250,000 shares were sold for gross proceeds of $1,961,500.
Recursion Pharmaceuticals, Inc. 的高管和董事Christopher Gibson計劃在2024年09月04日出售公司的20000股A類股份，預計市值爲120800美元。這些股份最初是在2016年09月01日作爲創始股份獲得的，這是來自發行人的一種形式的補償。這次計劃的賣出是在過去三個月中一系列交易的後續，前三個月總共售出了25萬股，總收入爲1961500美元。
Recursion Pharmaceuticals, Inc. 的高管和董事Christopher Gibson計劃在2024年09月04日出售公司的20000股A類股份，預計市值爲120800美元。這些股份最初是在2016年09月01日作爲創始股份獲得的，這是來自發行人的一種形式的補償。這次計劃的賣出是在過去三個月中一系列交易的後續，前三個月總共售出了25萬股，總收入爲1961500美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。